Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Vaccine - 4 Feb 2013

Hong Eva, Giuliani Marzia Monica, Deghmane Ala-Eddine, Comanducci Maurizio, Brunelli Brunella, Dull Peter, Pizza Mariagrazia, Taha Muhamed-Kheir

Abstract excerpt

A new vaccine, 4CMenB, is composed of surface proteins of Neisseria meningitidis and is aimed to target serogroup B (MenB) isolates. The vaccine components are present in meningococcal isolates of other serogroups allowing potential use against meningococcal isolates belonging to non-B serogroups. Isolates of serogroup X (MenX) have been emerged in countries of the African meningitis belt. 4CMenB may offer a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Africa
Share to Antigens, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Bactericidal Activity

Share to France

Share to Meningitis, Meningococcal

Share to Meningococcal Vaccines

Share to Microbial Viability

Share to Neisseria meningitidis

Source

Identifiers

PMID: 23261039
DOI: 10.1016/j.vaccine.2012.12.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?PMID 23261039Read ↗

Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolatesSemantic proximity Read ↗

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineSemantic proximity Read ↗

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effectSemantic proximity Read ↗

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.Semantic proximity Read ↗

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageSemantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

BexseroSemantic proximity Read ↗

Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years; Vaccine Efficiency PrognosisSemantic proximity Read ↗

A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccineSemantic proximity Read ↗

Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009Semantic proximity Read ↗

Meningococcal serogroup B vaccines: Estimating breadth of coverageSemantic proximity Read ↗

Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United StatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.